Alpha Cognition Inc at SNN Network Summer Event (Virtual) Transcript
Good day and welcome to the SNN Network Summer Virtual Event. Our next presenting company is Alpha Cognition.
It is now my pleasure to turn the floor over to Michael McFadden, CEO of Alpha Cognition. Sir, the floor is yours.
Thank you, operator. I'm excited to tell and update everyone on Alpha Cognition's story, our pipeline, and our latest clinical developments.
I will be discussing some forward-looking statements, so please consult the slide if you have questions about the implications of those.
Alpha Cognition is a late-stage biopharma company. We're focused on neurodegenerative diseases. Our lead compound is ALPHA-1062 for the treatment of mild to moderate Alzheimer's dementia. We believe we formulated this compound to be a best-in-class treatment.
We've designed it to optimize some of the limiting effects of current agents in the market, one of those is efficacious dose, getting to that dose quickly. Second is limiting side effects, and third and most
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
